#38455 04-21-2005 07:43 AM | Joined: Nov 2002 Posts: 3,552 Patient Advocate (old timer, 2000 posts) | Patient Advocate (old timer, 2000 posts) Joined: Nov 2002 Posts: 3,552 | Hi All, I too have been following this thread with great interest. I could have sworn that I read this is a small patient group - 6-20 patients and in Canada. What are the possibilities of entering a clinical trial in a foreign country? Also, isn't phase 1 typically about determining levels of toxicity more than therapeutic benefit which is more of a phase 2 thing. More Brian can expound a little on this.
Gary Allsebrook *********************************** Dx 11/22/02, SCC, 6 x 3 cm Polypoid tumor, rt tonsil, Stage III/IVA, T3N0M0 G1/2 Tx 1/28/03 - 3/19/03, Cisplatin ct x2, IMRT, bilateral, with boost, x35(69.96Gy) ________________________________________________________ "You are a mist that appears for a little while and then vanishes" (James 4:14 NIV)
| | |
#38456 04-21-2005 08:16 AM | Joined: Apr 2005 Posts: 58 Supporting Member (50+ posts) | OP Supporting Member (50+ posts) Joined: Apr 2005 Posts: 58 | Hi, Gary --
You are correct both on the size/location and the focus of the study.
As for being able to participate in a "foreign" study, there is no easy answer. It really is a study by study determination. Suffice it to say that there are many, many cross-border studies.
This one, given its size, would probably require either moving to Canada or, perhaps, getting your doctor registered as a study investigator. His/her affiliated hospital may balk at that for a single patient.
As for the focus of the study, yes it is an MTD study and has been designed to give statistical picture of the maximum tolerable dose. It is not designed, from a statistical perspective, to provide insight into therapeutic value.
That being said, to say that it deals in toxicity only is somewhat misleading. If it were designed ONLY to determine toxicity, the eligbility criteria would be healthy individuals. Here they are looking for participants from the patient population that they eventually hope will be therapeutically served. Thus, they must have shown some evidence of efficacy (even if it were only anecdotal) otherwise the ethics committee overseeing the study design would not have approved the design. This of course may not hold true in, say, Belarus . . . .
I am not an MD or even a researcher. I have had a good deal of exposure over the past couple of years to a wide variety of drug studies and study designs including transnational studies, however.
SCC Right Tonsil, T2N1M0, Dx 12/04, Tx 40 radiation (180 rad), 8 Chemo (carbo), Tx ended 3/15/05, Selective neck dissection 5/24/05, 22 nodes, 4 levels, no evidence of metastatic malignancy!!! :-)
| | |
Forums23 Topics18,168 Posts196,925 Members13,103 | Most Online458 Jan 16th, 2020 | | | |